iBio, Inc. (IBIO)
| Market Cap | 73.03M +400.2% |
| Revenue (ttm) | 300,000 -20.0% |
| Net Income | -27.61M |
| EPS | -0.39 |
| Shares Out | 49.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,840,818 |
| Open | 1.470 |
| Previous Close | 1.490 |
| Day's Range | 1.440 - 1.500 |
| 52-Week Range | 0.715 - 3.820 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 5.40 (+267.35%) |
| Earnings Date | Sep 4, 2026 |
About IBIO
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its... [Read more]
Financial Performance
In fiscal year 2025, iBio, Inc.'s revenue was $400,000, an increase of 77.78% compared to the previous year's $225,000. Losses were -$18.38 million, -26.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for IBIO stock is "Strong Buy." The 12-month stock price target is $5.4, which is an increase of 267.35% from the latest price.
News
iBio, Inc. Proxy statement: Proxy filing
iBio, Inc. filed a proxy statement on August 20, 2026, providing details for shareholder voting and corporate governance matters.
iBio appoints Molly Carr as chief medical officer
iBio (IBIO) announced the appointment of Molly Carr as chief medical officer as the company advances its clinical-stage cardiometabolic pipeline. Most recently, she served as clinical head and associa...
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary dis...
iBio announces new preclinical data from IBIO-610 study
iBio (IBIO) announced new preclinical data from its obese non-human primate, or NHP, study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Following a single dose of IB...
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach
iBio initiated with an Outperform at Raymond James
Raymond James initiated coverage of iBio (IBIO) with an Outperform rating and $5 price target iBio’s first antibody, IBIO-600, recently entered the clinic for obesity and the firm sees IBIO-610…
iBio, Inc. Transcript: Jefferies Global Healthcare Conference 2026
The portfolio targets obesity and related diseases post-GLP-1, focusing on muscle preservation, fat-specific weight loss, and weight maintenance. Lead programs are advancing through clinical milestones, leveraging unique antibody approaches for efficacy, safety, and scalability.
iBio to Participate in Upcoming Healthcare Investor Conferences
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO) (“iBio” or the “Company”), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases,...
iBio doses first participant in IBIO-600 trial
iBio (IBIO) announced the dosing of the first participant in its Phase 1 clinical trial of IBIO-600, the company’s most advanced obesity and cardiometabolic asset and its first program to…
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition
iBio, Inc. Slides: Corporate presentation
iBio, Inc. has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
iBio reports Q3 EPS (7c), consensus (6c)
“This last quarter was marked by significant advancement across our full pipeline. Most importantly, we received the clearance to enter the clinic with IBIO (IBIO)-600, which we believe has best-in-cl...
iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
Received regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with pr...
iBio, Inc. Earnings release: Q3 2026
iBio, Inc. released its Q3 2026 earnings on May 12, 2026, summarizing the period's financial results.
iBio, Inc. Quarterly report: Q3 2026
iBio, Inc. has published its Q3 2026 quarterly earnings report on May 12, 2026.
iBio, Inc. Transcript: Status update
AI-driven integration with experimental validation accelerates antibody drug discovery, enabling rapid clinic approval and overcoming immune tolerance for challenging targets. Generative models produce compact, functional antigen mimics, and future innovation is expected from simultaneous engineering of both antibody and antigen.
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
iBio (IBIO) announced IBIO-600 has received clinical trial notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human Research Ethics Committee, en...
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First participants expected to be dosed in 2Q 2026 SAN ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Alpha Cognition (ACOG), 135.11% surge in interest iBio (I...
iBio, Inc. Transcript: Study update
A bispecific antibody program targeting myostatin, GDF11, and activin A is advancing for PH-HFpEF, aiming for disease modification with improved safety over existing ligand traps. Preclinical data support efficacy, and a development candidate is expected to be announced in Q3.
iBio to provide update on cardiopulmonary program
iBio (IBIO) “announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio’s strategic pipeline expansion into pulmonary hypertension…
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET
iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a diversified cardiometabolic pipeline, highlighted by its Activin E antibody program, with key clinical milestones expected over the next 12–18 months. Its AI-enabled platform and strong financial position support rapid development and strategic flexibility. The team’s persistence and integrated approach set it apart in a competitive landscape.
iBio announces new preclinical data from study evaluating IBIO-610
iBio (IBIO) announced new preclinical data from its obese non-human primate study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. The preclinical body composition data ...
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total ...